Wynn Capital LLC Purchases 14,220 Shares of Pfizer Inc. (NYSE:PFE)

Wynn Capital LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 64.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,279 shares of the biopharmaceutical company's stock after purchasing an additional 14,220 shares during the quarter. Wynn Capital LLC's holdings in Pfizer were worth $919,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the fourth quarter worth $30,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $23.36 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a fifty day moving average price of $22.95 and a 200-day moving average price of $25.00. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $132.81 billion, a PE ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.82 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.36%. Pfizer's dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.